Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 22:15:1407669.
doi: 10.3389/fphar.2024.1407669. eCollection 2024.

Shuxuening injection for treating acute ischemic stroke: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials

Jie Zhan  1   2 , Xiaowen Xu  3 , Yanzhen Zhu  2 , Lin Liu  3 , Hongxia Chen  1   3   2 , Lechang Zhan  1   2
Affiliations

Shuxuening injection for treating acute ischemic stroke: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials

Jie Zhan et al. Front Pharmacol. .

Abstract

Background: Using Shuxuening injection (SXNI) for acute ischemic stroke (AIS) is popular in China, but its efficacy and safety remain controversial. Purpose: This study aims to assess the efficacy and safety of SXNI as an add-on therapy for AIS. Study design: Systematic review and meta-analysis. Methods: We searched for randomized controlled trials (RCTs) on SXNI for AIS in seven databases and two clinical trial registration platforms from their inception to January 2023. We used the Cochrane risk of bias tool to assess the methodological quality of the included studies and performed the meta-analysis with R software. The primary outcome was clinical efficacy, assessed by the clinical effective rate (CER). The secondary outcomes were neurological function, activities of daily living (ADL), and adverse events (AEs). Results: In total, 116 studies with 12,401 participants were included in this review. Fifteen (12.9%) studies were judged to be of moderate to high quality. SXNI plus conventional treatments (CTs) improved the CER compared with CTs alone (risk ratio [RR]: 1.21, 95% confidence interval [CI]: 1.17-1.25, p < 0.0001) or CTs plus other injections (RR: 1.18, 95% CI: 1.15-1.21, p < 0.0001). SXNI plus CTs reduced the National Institute of Health Stroke Scale score compared with CTs alone (mean difference [MD]: -4.00, 95% CI: -5.22 to -2.78, p < 0.0001) or CTs plus other injections (MD: -2.28, 95% CI: -3.41 to -1.16, p < 0.0001). SXNI plus CTs also decreased the Chinese Stroke Scale score compared with CTs alone (MD: -5.01, 95% CI: -7.38 to -2.65, p < 0.0001) or CTs plus other injections (MD: -4.31, 95% CI: -5.75 to -2.88, p < 0.0001). SXNI plus CTs was superior for increasing the Barthel index score compared with CTs alone (MD: 11.58, 95% CI: 8.27-14.90, p < 0.0001) or CTs plus other injections (MD: 5.43, 95% CI: 0.48-10.39, p = 0.0317). The level of evidence for each outcome was assessed as low to very low. The most common AEs of SXNI were cardiovascular system events, and all these AEs were mild. Conclusion: SXNI combined with CTs maybe better than CTs alone or CTs plus other injections for improving the clinical efficacy, neurological function, and ADL of AIS patients, with relatively reliable safety. However, due to the low quality of the included studies, more rigorously designed RCTs with large sample sizes should be conducted in the future.

Systematic review registration: www.crd.york.ac.uk, identifier (CRD42023418565).

Keywords: acute ischemic stroke; meta-analysis; shuxuening injection; systematic review; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA flowchart of study selection.
FIGURE 2
FIGURE 2
Risk of bias graph.
FIGURE 3
FIGURE 3
Forest plot and meta-analysis of clinical efficacy. (Note: CER, clinical effective rate; CTs, conventional treatments; SXNI, shuxuening injection).
FIGURE 4
FIGURE 4
Funnel plots based on the CER, NIHSS, and CSS scores. (Note. CER, clinical effective rate; CSS, Chinese Stroke Scale; CTs, conventional treatments; NIHSS, National Institutes of Health Stroke Scale; SXNI, shuxuening injection).
FIGURE 5
FIGURE 5
Forest plot and meta-analysis of neurological function. (Note. CSS, Chinese Stroke Scale; CTs, conventional treatments; NIHSS, National Institutes of Health Stroke Scale; SXNI, shuxuening injection).
FIGURE 6
FIGURE 6
Forest plot and meta-analysis of activities of daily living. (Note. BI, Barthel index; CTs, conventional treatments; SXNI, shuxuening injection).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ahlemeyer B., Krieglstein J. (2003). Neuroprotective effects of Ginkgo biloba extract. Cell Mol. Life Sci. 60 (9), 1779–1792. 10.1007/s00018-003-3080-1 - DOI - PMC - PubMed
    1. Bhatia R., Hill M. D., Shobha N., Menon B., Bal S., Kochar P., et al. (2010). Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 41 (10), 2254–2258. 10.1161/STROKEAHA.110.592535 - DOI - PubMed
    1. Brott T., Adams H. P., Jr, Olinger C. P., Marler J. R., Barsan W. G., Biller J., et al. (1989). Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20 (7), 864–870. 10.1161/01.str.20.7.864 - DOI - PubMed
    1. Cai L. M., Jiang J. Z. (2012). Summary analysis of the efficacy of Shuxuening injection for acute cerebral infarction. Hebei Med. J. 34 (8), 1217–1219. 10.3969/j.issn.1002-7386.2012.08.058 - DOI
    1. Chandrasekaran K., Mehrabian Z., Spinnewyn B., Drieu K., Fiskum G. (2001). Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res. 922 (2), 282–292. 10.1016/s0006-8993(01)03188-2 - DOI - PubMed

Publication types

LinkOut - more resources